AFP and hepatocellular carcinoma: In a prospective open-label, phase 1 clinical trial of nivolumab plus Y90 TARE in patients with advanced HCC, 9 (81%) and 6 (46%) out of 11 patients exhibited stable disease and reduced serum AFP levels, respectively (NCT02837029) [103].